Discontinued — last reported Q1 '26

Products & Services · Sales

Winrevair — Sales

Merck & Co. Winrevair — Sales decreased by 43.9% to $525.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.3%, from $560.00M to $525.00M. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates successful market penetration and growing demand, while a decrease may signal competitive pressure or loss of market share.

Detailed definition

This metric measures the total gross revenue generated from the commercial sale of a specific pharmaceutical product wit...

Peer comparison

Standard across the pharmaceutical industry as product-level revenue reporting, comparable to top-line sales figures for specific blockbuster drugs at peer companies.

Metric ID: mrk_segment_winrevair_sales

Historical Data

15 periods
 Q1 '22Q2 '22Q3 '22Q4 '22Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0.00$0.00$0.00$0.00$0.00$0.00$0.00$140.00M$299.00M$399.00M$560.00M$671.00M$720.00M$935.00M$525.00M
QoQ Change+113.6%+33.4%+40.4%+19.8%+7.3%+29.9%-43.9%
YoY Change+379.3%+140.8%+134.3%-6.3%
Range$0.00$935.00M
Avg YoY Growth+162.0%
Median YoY Growth+137.6%

Frequently Asked Questions

What is Merck & Co.'s winrevair — sales?
Merck & Co. (MRK) reported winrevair — sales of $525.00M in Q1 2026.
How has Merck & Co.'s winrevair — sales changed year-over-year?
Merck & Co.'s winrevair — sales decreased by 6.3% year-over-year, from $560.00M to $525.00M.
What does winrevair — sales mean?
The total revenue earned from selling this specific drug to customers.